Celgene Corporation (NASDAQ:CELG) is reaping the fruits of its speedy efforts in which the company made quite a number of lucrative deals and transactions.
The company is now enjoying some good times though it has not been smooth sailing in the past. It has been a treacherous road full of uncertainties as well as irregular market conditions but luckily all the effort has paid off.
Celgene’s success is attributed to the various pivotal foundations that it has set itself upon. Some of the ventures in its history include the investment opportunity where the company tossed in $485 million in the acquisition of a cancer genomics firm. This one was particularly important as a part of the company to venture into cancer treatments.
Another investment decision that the company made is the purchase of shares worth $450 million in an immune oncology firm. Some of the money spending strategies has been costly such as the company’s $30 million licensing contract. Luckily it is also one of the ways in which the company has benefited. Not to come to an end but one of the other influential deals is the $80 million investment in one of the company’s partners.
All these deals and a few more have placed Celgene as one of the most successful and creative deal makers in history. While most companies might experience stretched resources from such ventures, Celgene has managed to emerge even stronger and more lucrative. This is because their investment strategies are well thought out, and a lot of consideration goes into the whole process.
Company CEO Bob Hugin also stated that his firm has the right knowledge and business principles that are vital to maintaining the continued success of the ventures. The biotech company is not just focused on deal making. It has used most of the opportunities presented to get to work and come up with outstanding solutions. A good example is the partnership with Acceleron Pharma Inc (NASDAQ:XLRN) which yielded revolutionary treatments for conditions such as myelodysplastic syndromes.
